

Ný lyf á markað 1.12.2012

| Vnr | Lyfjaheiti | Lyfjaform | ATC | Styrkl. | Magn | | Pakkning | Afgr.- tilhöun | Auka upp- lýsingar | Umboðs- aðili | Markaðsleyfishafi |
|----------------|------------------------|-------------------------|---------|---------------|---------|---|-------------|-------------------|--------------------------|------------------|---|
| Lyf fyrir menn | | | | | | | | | | | |
| Ný lyf | | | | | | | | | | | |
| 050306 | Alfuzosin hydrochlorid | Forðatafla | G04CA01 | 10 mg | 90 stk. | | þp. | R | | | ratiopharm GmbH |
| 040735 | Azithromycin Actavis | Filmuhúðuð tafla | J01FA10 | 500 mg | 3 stk. | | þp. | R | | | Actavis Group PTC ehf. |
| 516219 | Azithromycin Eberth | Innrennslisstofn, lausn | J01FA10 | 500 mg | 10 ml | 1 | hgl. | R | | | Dr. Friedrich Eberth Arzneimittel GmbH |
| 103806 | Fentanyl ratiopharm | Forðaplástur | N02AB03 | 12 mcg/klst. | 5 stk. | | skammtapoki | R X | | | ratiopharm GmbH |
| 060114 | Fentanyl ratiopharm | Forðaplástur | N02AB03 | 25 mcg/klst. | 5 stk. | | skammtapoki | R X | | | ratiopharm GmbH |
| 060123 | Fentanyl ratiopharm | Forðaplástur | N02AB03 | 50 mcg/klst. | 5 stk. | | skammtapoki | R X | | | ratiopharm GmbH |
| 060132 | Fentanyl ratiopharm | Forðaplástur | N02AB03 | 75 mcg/klst. | 5 stk. | | skammtapoki | R X | | | ratiopharm GmbH |
| 060141 | Fentanyl ratiopharm | Forðaplástur | N02AB03 | 100 mcg/klst. | 5 stk. | | skammtapoki | R X | | | ratiopharm GmbH |
| 050010 | Finasterid LYFIS | Filmuhúðuð tafla | G04CB01 | 5 mg | 98 stk. | | þp. | R | | | LYFIS ehf. |
| 168618 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,15 ml | 1 | Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 168629 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,20 ml | 1 | Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 031201 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,25 ml | 1 | Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 168640 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,30 ml | 1 | Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 138318 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,35 ml | 1 | Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 168651 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,40 ml | 1 | Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |

Ný lyf á markað 1.12.2012

| Vnr | Lyfjaheiti | Lyfjaform | ATC | Styrkl. | Magn | | Pakkning | Afgr.- tilhöun | Auka upp- lýsingar | Umboðs- aðili | Markaðsleyfishafi |
|----------------|----------------------|------------------------------|---------|-----------|----------|------|------------|-------------------|--------------------------|------------------|---|
| Lyf fyrir menn | | | | | | | | | | | |
| Ný lyf | | | | | | | | | | | |
| 457692 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,45 ml | | 1 Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 168662 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,50 ml | | 1 Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 068811 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,55 ml | | 1 Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 465333 | Metoject | Stungulyf, lausn | L01BA01 | 50 mg/ml | 0,60 ml | | 1 Áf. spr. | R | | | medac Gesellschaft für klinische Spezialpräparate mbH |
| 008959 | Naso-ratiopharm | Nefúði, lausn | R01AA07 | 0,5 mg/ml | 10 ml | | 1 Glas | L | | | ratiopharm GmbH |
| 009270 | Naso-ratiopharm | Nefúði, lausn | R01AA07 | 1 mg/ml | 10 ml | | 1 Glas | L | | | ratiopharm GmbH |
| 533779 | Omeprazol Pensa | Magasýrupolið hart hylki | A02BC01 | 20 mg | 28 stk. | | þp. | L | | | Pensa Pharma AB |
| 066593 | Omeprazol Pensa | Magasýrupolið hart hylki | A02BC01 | 20 mg | 100 stk. | 2x50 | Töfluílát | R | | | Pensa Pharma AB |
| 445479 | Ropinirol Actavis | Forðatafla | N04BC04 | 2 mg | 84 stk. | | þp. | R | | | Actavis Group PTC ehf. |
| 497983 | Ropinirol Actavis | Forðatafla | N04BC04 | 4 mg | 84 stk. | | þp. | R | | | Actavis Group PTC ehf. |
| 504014 | Ropinirol Actavis | Forðatafla | N04BC04 | 8 mg | 84 stk. | | þp. | R | | | Actavis Group PTC ehf. |
| 379796 | Ropinirole Portfarma | Forðatafla | N04BC04 | 2 mg | 84 stk. | | Töfluílát | R | | | Portfarma ehf. |
| 382162 | Ropinirole Portfarma | Forðatafla | N04BC04 | 4 mg | 84 stk. | | Töfluílát | R | | | Portfarma ehf. |
| 094757 | Ropinirole Portfarma | Forðatafla | N04BC04 | 8 mg | 84 stk. | | Töfluílát | R | | | Portfarma ehf. |
| 191079 | Rosuvastatin Actavis | Filmuhúðuð tafla | C10AA07 | 10 mg | 98 stk. | | þp. | R | | | Actavis Group PTC ehf. |
| 173284 | Rosuvastatin Actavis | Filmuhúðuð tafla | C10AA07 | 20 mg | 98 stk. | | þp. | R | | | Actavis Group PTC ehf. |
| 180500 | Tamsulosin Medical | Hart hylki m. br. losunarhr. | G04CA02 | 0,4 mg | 100 stk. | | þp. | R | | | Medical ehf. |
| 091493 | Trajenta | Filmuhúðuð tafla | A10BH05 | 5 mg | 30 stk. | | þp. | R | | Vistor hf. | Boehringer Ingelheim International G.m.b.H |

Ný lyf á markað 1.12.2012

| Vnr | Lyfjaheiti | Lyfjaform | ATC | Styrkl. | Magn | Pakkning | Afgr.- tilhöun | Auka upp- lýsingar | Umboðs- aðili | Markaðsleyfishafi |
|--------------------|----------------------|----------------------|----------|-----------------|---------|----------------|-------------------|--------------------------|------------------|--|
| Lyf fyrir menn | | | | | | | | | | |
| Ný lyf | | | | | | | | | | |
| 518897 | Trajenta | Filmuhúðuð tafla | A10BH05 | 5 mg | 90 stk. | þp. | R | | Vistor hf. | Boehringer Ingelheim International G.m.b.H |
| Ný pakkningarstærð | | | | | | | | | | |
| 099863 | Sutent | Hart hylki | L01XE04 | 12,5 mg | 28 stk. | þp. | R Z | | Icepharma hf. | Pfizer Ltd. |
| Nýr styrkleiki | | | | | | | | | | |
| 487692 | Enbrel | Sts og leysir, lausn | L04AB01 | 10 mg | 10 mg | 4 hgl. | R Z | | Icepharma hf. | Pfizer Ltd. |
| Breytt Vnr | | | | | | | | | | |
| 097498 | Efexor Depot | Hart forðahylki | N06AX16 | 37,5 mg | 7 stk. | þp. | R | 020277 | Icepharma hf. | Pfizer ApS |
| 467480 | IntronA (Alfatronol) | Stungulyf, lausn | L03AB05 | 18.000.000 a.e. | 1 stk. | Áf. lyfjap. | R Z | 584133 | Vistor hf. | Merck Sharp & Dohme Limited |
| 467621 | IntronA (Alfatronol) | Stungulyf, lausn | L03AB05 | 60.000.000 a.e. | 1 stk. | Áf. lyfjap. | R Z | 487725 | Vistor hf. | Merck Sharp & Dohme Limited |
| 576714 | Puri-nethol | Tafla | L01BB02 | 50 mg | 25 stk. | Töfluílát | R | 164251 | | Aspen Pharma Trading Limited |
| 482457 | Treo | Freyðitafla | N02BA51 | 50/500 mg/mg | 20 stk. | Töfluílát | L | 504191 | Vistor hf. | Meda AB |
| 121302 | Treo | Freyðitafla | N02BA51 | 50/500 mg/mg | 60 stk. | 3x20 Töfluílát | L | 128777 | Vistor hf. | Meda AB |
| 491313 | Zarzio | Stl/ir.lausn | L03AA02 | 30 millj.ein. | 0.5 ml | 5 Áf. spr. | R Z | 062761 399746 | Sandoz GmbH | Sandoz GmbH |
| Lyf fyrir dýr | | | | | | | | | | |
| Breytt Vnr | | | | | | | | | | |
| 540970 | Equest Pramox vet. | Hlaup til inntöku | QP54AB52 | | 1 stk. | Dæla | R | 063923 | Icepharma hf. | Pfizer Oy Animal Health |